SGLT2 i physiologically elevates blood ketone bodies such as β-hydroxybutyrate, which can modulate NLRP3 inflammasome-IL-1β signaling, and a key pathologic pathway in AD. This evidence concerns the gene NLRP3 and Alzheimer disease.